头孢丙烯与头孢克洛随机对照治疗下呼吸道感染患者的临床评价  

Randomized controlled clinical trial of cefprozil vs cefaclor in treatment of lower respiratory tract infection

作　　者：王业建[1] 熊飞升 周卫民[1] 邢武[1] 李洪[2] 

机构地区：[1]郑州市第六人民医院内科,河南郑州450005 [2]华中科技大学同济医学院附属协和医院呼吸内科,湖北武汉430022

出　　处：《临床荟萃》2003年第21期1221-1223,共3页Clinical Focus

摘　　要：目的　评价头孢丙烯与头孢克洛随机对照治疗下呼吸道感染的疗效和安全性。方法　轻、中度下呼吸道感染患者 12 0例随机分成两组 ,头孢丙烯组 6 2例予头孢丙烯 5 0 0mg ,口服 ,2次 /d ;头孢克洛组 5 8例予头孢克洛5 0 0mg ,口服 ,3次 /d。两组均以 7～ 14天为 1个疗程。结果　头孢丙烯组与头孢克洛组的临床有效率分别为 91.9%与 89.7% (P >0 .0 5 ) ,细菌消除率为 89.8%与 88.9% (P >0 .0 5 ) ,两组均无明显不良反应。结论　头孢丙烯可作为治疗轻。Objective To evaluate the efficacy and safety of cefprozil in the treatment of lower respiratory tract infections. Methods One hundred and twenty patients with mild to moderate lower respiratory tract infection were divided into two groups. Sixty two patients were treated with cefprozil 500 mg, orally,twice a day, Fifty eight patients were treated with cefaclor 500 mg,orally,threetimes a day. In both groups 7-14 d was a treatment course. Results The total clinical effective rates of cefprozil and cefaclor were 91.9 % and 89.7 % ( P > 0.05 ), respectively. The bacterial clearance rates were 89.8 % and 88.9 % ( P > 0.05 ), respectively. Both groups showed no obvious adverse reactions. Conclusion Cefprozil is a safe and potent antibacterial agent in treating mild to moderate lower respiratory tract infection.

关 键 词：头孢丙烯 头孢克洛 呼吸道感染 随机对照治疗 疗效 安全性 临床评价 

分 类 号：R562[医药卫生—呼吸系统] R974[医药卫生—内科学]